FDA Approves PGDx Elio Tissue Complete CDx for Advanced Melanoma
The FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma, according to Labcorp. The test detects BRAF V600E and V600K in FFPE tissue to identify patients for FDA-approved BRAF inhibitor or BRAF/MEK regimens. Labcorp reported PPA 98.3% (V600E) and 94.7% (V600K), with results in 4 to 5 days.
How this was made
The 30-second read
Why it matters
FDA PMA approval (P250036) makes the assay a companion diagnostic, enabling qualified health professionals to use it to select patients for FDA-approved BRAF inhibitors or BRAF/MEK combinations. The kit-based, in-house implementation could shorten biopsy-to-treatment timelines and reduce reliance on external reference labs.
Market read
This is a direct regulatory catalyst for Labcorp’s oncology diagnostics portfolio, likely supportive for sentiment around its precision medicine testing capabilities.
What to watch
The article lacks reimbursement details, competitive landscape versus other BRAF companion diagnostics, and any quantified expected test volumes or payer coverage, which are key for near-term earnings impact.
Background
Labcorp’s PGDx elio tissue complete CDx is an NGS-based in vitro diagnostic intended to identify BRAF V600E and V600K mutations in melanoma tissue to guide targeted therapy eligibility.
Ticker impact
FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma with BRAF V600E/V600K variants.
Modest positive bias for LH shares, with near-term impact likely limited unless management ties approval to material financial guidance or uptake metrics.
The article is a concrete FDA PMA approval for a specific companion diagnostic, which is a real commercial catalyst, but it provides no revenue, volume, or guidance figures to size the financial impact.
Market effects
Strengthens the FDA-approved companion diagnostic pathway for BRAF-mutant melanoma, potentially increasing demand for NGS oncology panels and related lab services.
Primarily US healthcare delivery impact as the approval enables in-house hospital testing workflows.
US regulatory approval may support broader adoption in other markets over time, but the article is US-focused.
Counterpoint
Approval does not guarantee rapid utilization; adoption may be constrained by clinician ordering patterns, reimbursement, and competing assays already in hospital formularies.
Key entities
- companyLabcorp
Company receiving FDA approval for PGDx elio tissue complete CDx companion diagnostic.
- subsidiaryPersonal Genome Diagnostics Inc.
Labcorp subsidiary that submitted the PMA application (received 2025-09-10; decision 2026-07-30).
- regulatorFDA
Approved the companion diagnostic under PMA P250036.
